Key result
Elevated BNP in severe sepsis is linked to systolic myocardial dysfunction and higher ICU mortality.
Why the study?
The value of brain natriuretic peptide plasma levels as a marker of systolic myocardial dysfunction and prognosis during severe sepsis and septic shock was investigated.
Does plasma brain natriuretic peptide level correlate with systolic myocardial dysfunction and mortality in patients with severe sepsis or septic shock?
Observational (n=34)
No
Does plasma brain natriuretic peptide level correlate with systolic myocardial dysfunction and mortality in patients with severe sepsis or septic shock?
Elevated plasma BNP levels in patients with severe sepsis or septic shock are associated with systolic myocardial dysfunction and increased ICU mortality.
Answers are grounded in this paper and cite their sources.
BNP may flag myocardial dysfunction and ICU mortality risk in sepsis; leaves open whether monitoring alters management.
Objective To investigate the value of brain natriuretic peptide plasma levels as a marker of systolic myocardial dysfunction during severe sepsis and septic shock. Design Prospective observational study. Setting Intensive care unit. Patients A total of 34 consecutive patients with severe sepsis (nine patients) or septic shock (25 patients) without previous cardiac, respiratory, or chronic renal failure. Interventions None. Measurements and main results Myocardial systolic performance was assessed by fractional area contraction (FAC) using echocardiography performed on days 2 (FACD2) and 8. Plasma levels of brain natriuretic peptide were measured at days 1-4 and 8 after the beginning of severe sepsis. Among 34 patients (Simplified Acute Physiology Score II, 43 +/- 2.5), 15 (44%) presented with initial myocardial dysfunction (FACD2 < 50%). Lungs were the origin of sepsis in 65% of patients. The 28-day mortality was 29%. Comparisons were performed between patients with (FACD2 < 50%) and without (FACD2 > or = 50%) myocardial dysfunction. Plasma levels of brain natriuretic peptide were significantly higher in patients with FACD2 < 50% than in those with FACD2 > or = 50% (p <.05) from day 2 to day 4. Brain natriuretic peptide levels were also significantly higher on days 2 and 3 in patients who died during their intensive care unit stay (p <.05). Conclusions Systolic myocardial dysfunction is present in 44% of patient with severe sepsis or septic shock. In this setting, brain natriuretic peptide seems useful to detect myocardial dysfunction, and high plasma levels appear to be associated with poor outcome of sepsis, but further studies are needed.
No takes yet. Share an insight, caveat, or question.
Charpentier et al. (2004) conducted an observational in Severe sepsis and septic shock (n=34). Systolic myocardial dysfunction (FACD2 < 50%) and plasma brain natriuretic peptide levels vs. No systolic myocardial dysfunction (FACD2 >= 50%) was evaluated on Plasma brain natriuretic peptide levels in relation to systolic myocardial dysfunction (FACD2 < 50%) and ICU mortality (p=<0.05). Plasma BNP levels were higher in severe sepsis patients with systolic myocardial dysfunction and in ICU non-survivors.
Synapse has enriched 10 related papers. Consider them for comparative context: